Four views: Future prospects for the weight-loss sector
Portfolio Adviser asks this month’s panel for their views on the future prospects for a healthcare sector that seems to be booming
Portfolio Adviser asks this month’s panel for their views on the future prospects for a healthcare sector that seems to be booming
|
|
There is value to be found in the industries immune to the AI revolution, writes Kepler’s Ryan Lightfoot-Aminoff
|
|
Three fund managers share stocks that are making a difference
|
|
There are still plenty of undervalued equities to take advantage of despite soaring tech shares, writes Mike Coop
|
|
Obesity drugs are at a revolutionary moment comparable to the launch of the iPhone, writes Ben Kluftinger
|
|
Exciting developments are underway in the healthcare world, and these three companies are leading that change
|
|
Antidiabetic drugs such as Ozempic have markets excited about healthcare, but AllianceBernstein’s Vinay Thapar calls for caution amongst the hype
|
|
Catherine Tennyson joins from Point 72 Asset Management
|
|
Demand for GLP-1 medications is skyrocketing
|
|
The sector looks set to thrive again this year after a strong 2023, but there is more to tech than just AI
|
|
The global equity team discusses AI, the energy transition, global travel and healthcare efficiency
|
|
European equity funds bruised by global manufacturing slowdown
|
|